DYN
NASDAQDyne Therapeutics Inc.
Price$14.25-0.79 (-5.22%)
01:30 PM07:45 PM
News · 26 weeks149-70%
2026-04-192026-10-11
Mix4490d
- SEC Filings17(39%)
- Other11(25%)
- Insider10(23%)
- Offering4(9%)
- Analyst2(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Dyne Therapeutics Inc.4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECDyne Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
- PRDyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months - - Data continued to support improvement at 6 months in video hand opening time (vHOT) as an early indicator of clinical benefit with z-basivarsen in DM1 - - Dyne continues to expect topline data in Q1 2027 from the ACHIEVE registrational expansion cohort (REC), with a primary endpoint of change from baseline in vHOT at 6 months, intended to support a potential submission for U.S. Accelerated Approval in Q3 2027 - - The mean
- PRDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 14 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 278,100 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common sto
- ANALYSTDyne Therapeutics downgraded by Analyst with a new price targetAnalyst downgraded Dyne Therapeutics from Neutral to Underweight and set a new price target of $10.00
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- INSIDERChief Commercial Officer Friedl-Naderer Johanna sold $25,408 worth of shares (1,085 units at $23.42) as part of a pre-agreed trading plan, decreasing direct ownership by 0.70% to 152,897 units (SEC Form 4) to cover taxes4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERChief Medical Officer Kerr Douglas sold $115,546 worth of shares (5,035 units at $22.95) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 162,564 units (SEC Form 4) (for withholding tax)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERCEO & President Cox John sold $106,823 worth of shares (5,658 units at $18.88) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 357,507 units (SEC Form 4) (tax withholding)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- PRDyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD - WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present preclinical data supporting the ongoing development of DYNE-253, DYNE-245, D
- PRDyne Therapeutics to Participate in Upcoming Investor ConferencesWALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference, fireside chat on Friday, September 11, 2026 at 10:20 a.m. ET in New York, NYMorgan Stanley 24th Annual Global Healthcare Conference, fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NYBaird 2026 Global Healthcare Conference, fireside chat on Tuesday, September 15, 2026 at 10:50 a.m. ET in New York
- PRDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 11 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 161,300 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stoc
- INSIDERDirector Rhodes Jason P sold $65,184,894 worth of shares (2,586,928 units at $25.20) as part of a pre-agreed trading plan (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERChief Commercial Officer Friedl-Naderer Johanna sold $5,939 worth of shares (226 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.15% to 153,982 units (SEC Form 4) to satisfy withholding tax4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERChief Medical Officer Kerr Douglas sold $40,892 worth of shares (1,556 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.92% to 167,599 units (SEC Form 4) to satisfy withholding tax4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERCEO & President Cox John sold $131,032 worth of shares (4,986 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 363,165 units (SEC Form 4) to satisfy withholding tax4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERChief Financial Officer Lucera Erick sold $47,225 worth of shares (1,797 units at $26.28) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 119,766 units (SEC Form 4) to satisfy withholding obligation4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
DYN FAQ
7 questionsWhat does Dyne Therapeutics Inc. do?
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.Where does DYN stock trade?
Dyne Therapeutics Inc. (DYN) is listed on NASDAQ.What sector and industry is DYN in?
Dyne Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dyne Therapeutics Inc. go public?
Dyne Therapeutics Inc. (DYN) completed its IPO in 2020.What are analysts saying about DYN?
Dyne Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Underweight with a $1000.00 price target on 2026-09-09. Recent price targets range from $1000.00 to $4000.00.What companies are similar to DYN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DYN side-by-side with any of them on Quantisnow.How can I track DYN on Quantisnow?
Quantisnow aggregates Dyne Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DYN to receive live email and push alerts on every new disclosure.